Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash flows from operating activities:
Net loss	$ (21,398)	$ (8,356)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	490	490
Accretion of premium/discount on investments	(473)	0
Non-cash lease expense	69	78
Stock-based compensation expense	6,445	631
Change in fair value of contingent consideration	401	299
Other non-cash reconciling items	(1)	16
Change in operating assets and liabilities:
Prepaid expenses, other current assets and other assets	81	(334)
Accounts payable	4,865	1,001
Accrued compensation	(1,909)	(954)
Accrued clinical trial site costs	(998)	309
Operating lease liabilities	(56)	(116)
Other liabilities	(44)	208
Net cash used in operating activities	(12,528)	(6,728)
Cash flows from investing activities:
Purchases of property and equipment	(11)	0
Purchases of marketable securities	(115,233)	0
Net cash used in investing activities	(115,244)	0
Cash flows from financing activities:
Proceeds from exercise of common stock warrants	923	0
Proceeds from exercise of stock options	15	0
Net cash provided by financing activities	938	0
Net decrease in cash and cash equivalents	(126,834)	(6,728)
Cash and cash equivalents, beginning of period	169,681	14,602
Cash and cash equivalents, end of period	42,847	7,874
Supplemental disclosure of non-cash financing information
Purchases of property and equipment included in accounts payable	$ 8	$ 0